SGEN : Analysis & Opinions

  1. Seattle Genetics, International Speedway And Others Insiders ...

    December 9, 2013
    Insiders may sell shares for any number of reasons, but conventional wisdom says that insiders really only buy shares of ...
  2. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  3. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  4. SGEN/Astellas to Co-Develop Another ADC - Analyst Blog

    June 28, 2013
    Seattle Genetics and Agensys, a subsidiary of Astellas announced that the former has exercised its option to co-develop one ...
  5. Bayer, Seattle Genetics Join Forces - Analyst Blog

    June 26, 2013
    Bayer inked a collaboration agreement with Seattle Genetics for the ADC technology.
  6. SGEN/Takeda Report Data on Adcetris - Analyst Blog

    June 21, 2013
    Seattle Genetics and partner Takeda reported results from a post-hoc analysis evaluating progression-free survival (PFS) ...
  7. Canada Approves Seattle Genetics' Adcetris - Analyst Blog

    February 4, 2013
    Seattle Genetics Inc. (SGEN) recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin). ...
  8. Celgene and More Big Movers in Healthcare on December 10, 2012

    December 10, 2012
    On a good day for the market, the Nasdaq is trading up 0.6%, the S&P 500 is up 0.2% and the Dow has increased 0.3%. The healthcare ...
  9. HCA and Other Healthcare Stocks Making Big Moves on November ...

    November 8, 2012
    This morning's trading has marked a bad day for the market so far. The Nasdaq has fallen 0.5%; the S&P 500 is down 0.2%; ...
  10. Intuitive Surgical and More Big Movers in Healthcare on October ...

    October 16, 2012
    The market has been doing well after the morning's trading. The Nasdaq is trading up 1.4%; the S&P 500 has increased 1%; ...
  11. Zimmer and More Big Movers in Healthcare on September 7, 2012

    September 7, 2012
    The Nasdaq is trading down 0.2%, the S&P 500 has risen 0.3% and the Dow has remained steady after the morning's trading. ...
  12. Endo Pharmaceuticals Holdings Inc and More Big Movers in Healthcare ...

    August 9, 2012
    The market is having a bad day so far. The Nasdaq is trading down 0.1%; the S&P 500 has decreased 0.2%; and the Dow has slipped ...
  13. Dendreon's Bull Story In Intensive Care

    August 10, 2011
    Dendreon shocks bulls with a poor revenue ramp for Provenge.
  14. Vical Gets Some Validation

    July 19, 2011
    Vical gets a small victory with a partnership for its CMV drug.
  15. Time For Gilead To Open Its Wallet

    July 6, 2010
    Gilead has carved out an exceptionally valuable niche, but should the company do more?
  16. Five Biotechs Worth Follow Up (BLUD, NUVA, SGEN)

    October 3, 2007
    Learn how investors can build their own healthcare ETF with a few top-rated stocks.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center